EGRX Eagle Pharmaceuticals Inc.

43.94
+0.83  (+2%)
Previous Close 43.11
Open 42.87
Price To Book 3.38
Market Cap 655284206
Shares 14,913,159
Volume 182,076
Short Ratio
Av. Daily Volume 284,137

SEC filingsSee all SEC filings

  1. 8-K - Current report 181201946
  2. 8-K - Current report 181168110
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181164886
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154484
  5. 8-K - Current report 181151944

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released October 30, 2018 did not meet primary endpoints.
Fulvestrant
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
PEMFEXY,
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer
Phase 2 trial ongoing.
Ryanodex
MDMA/meth intoxication
Phase 3 completion of enrollment announced August 30, 2018.
Ryanodex
Exertional heat stroke (EHS)

Latest News

  1. See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
  2. Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results
  3. Eagle Pharmaceuticals Announces Positive Results of Pre-clinical Study Conducted to Evaluate Effects of RYANODEX in Acute Radiation Syndrome (ARS)
  4. Investors Are Undervaluing Eagle Pharmaceuticals Inc (NASDAQ:EGRX) By 28.8%
  5. Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
  6. Moving Average Crossover Alert: Eagle Pharmaceuticals (EGRX)
  7. Edited Transcript of EGRX earnings conference call or presentation 1-Nov-18 12:30pm GMT
  8. Eagle Pharmaceuticals (EGRX) Q3 Earnings Match Estimates
  9. Eagle Pharmaceuticals: 3Q Earnings Snapshot
  10. Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results
  11. Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase as Part of New $150 Million Share Repurchase Authorization
  12. Eagle Pharmaceuticals Announces Results of Study for Fulvestrant
  13. Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2018 Financial Results on November 1, 2018
  14. Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A — Emerging Consolidated Expectations, Analyst Ratings
  15. Is Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Attractive At Its Current PE Ratio?
  16. Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure

SEC Filings

  1. 8-K - Current report 181201946
  2. 8-K - Current report 181168110
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181164886
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154484
  5. 8-K - Current report 181151944
  6. 8-K - Current report 181145479
  7. 8-K - Current report 181145475
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181116224
  9. 8-K - Current report 181103685
  10. 8-K - Current report 181103684